Sabrina Strano

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5430579/publications.pdf

Version: 2024-02-01

125 papers	7,644 citations	53794 45 h-index	54911 84 g-index
127 all docs	127 docs citations	127 times ranked	10333 citing authors

#	Article	IF	Citations
1	Gain of function of mutant p53: The mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell, 2006, 10, 191-202.	16.8	386
2	Physical Interaction with Yes-associated Protein Enhances p73 Transcriptional Activity. Journal of Biological Chemistry, 2001, 276, 15164-15173.	3.4	368
3	The Transcriptional Coactivator Yes-Associated Protein Drives p73 Gene-Target Specificity in Response to DNA Damage. Molecular Cell, 2005, 18, 447-459.	9.7	318
4	The circ<scp>RNA</scp>â€“micro<scp>RNA</scp> code: emerging implications for cancer diagnosis and treatment. Molecular Oncology, 2019, 13, 669-680.	4.6	300
5	Mutant p53: an oncogenic transcription factor. Oncogene, 2007, 26, 2212-2219.	5.9	241
6	PML, YAP, and p73 Are Components of a Proapoptotic Autoregulatory Feedback Loop. Molecular Cell, 2008, 32, 803-814.	9.7	224
7	Physical and Functional Interaction between p53 Mutants and Different Isoforms of p73. Journal of Biological Chemistry, 2000, 275, 29503-29512.	3.4	217
8	Physical Interaction with Human Tumor-derived p53 Mutants Inhibits p63 Activities. Journal of Biological Chemistry, 2002, 277, 18817-18826.	3.4	203
9	Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC. Nature Communications, 2012, 3, 865.	12.8	198
10	CircRNAs: role in human diseases and potential use as biomarkers. Cell Death and Disease, 2021, 12, 468.	6.3	191
11	The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. Nature Structural and Molecular Biology, 2009, 16, 1086-1093.	8.2	182
12	The oncogenic role of circPVT1 in head and neck squamous cell carcinoma is mediated through the mutant p53/YAP/TEAD transcription-competent complex. Genome Biology, 2017, 18, 237.	8.8	179
13	Mutant p53 Enhances Nuclear Factor ÎºB Activation by Tumor Necrosis Factor Î± in Cancer Cells. Cancer Research, 2007, 67, 2396-2401.	0.9	178
14	Pin1 Links the Activities of c-Abl and p300 in Regulating p73 Function. Molecular Cell, 2004, 14, 625-636.	9.7	165
15	miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer. Cell Death and Disease, 2012, 3, e423-e423.	6.3	160
16	<scp>YAP</scp> enhances the proâ€proliferative transcriptional activity of mutant p53 proteins. EMBO Reports, 2016, 17, 188-201.	4.5	154
17	SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells. Oncogene, 2012, 31, 3148-3163.	5.9	153
18	Oral mucositis: the hidden side of cancer therapy. Journal of Experimental and Clinical Cancer Research, 2020, 39, 210.	8.6	146

#	Article	IF	Citations
19	MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death and Differentiation, 2012, 19, 1038-1048.	11.2	136
20	Identification of Direct p73 Target Genes Combining DNA Microarray and Chromatin Immunoprecipitation Analyses. Journal of Biological Chemistry, 2002, 277, 43359-43368.	3.4	125
21	The Transcriptional Repressor ZEB Regulates p73 Expression at the Crossroad between Proliferation and Differentiation. Molecular and Cellular Biology, 2001, 21, 8461-8470.	2.3	117
22	EGF Decreases the Abundance of MicroRNAs That Restrain Oncogenic Transcription Factors. Science Signaling, 2010, 3, ra43.	3.6	100
23	YAP: At the crossroad between transformation and tumor suppression. Cell Cycle, 2009, 8, 49-57.	2.6	99
24	Urinary 6-Sulfatoxymelatonin Levels and Risk of Breast Cancer in Postmenopausal Women. Journal of the National Cancer Institute, 2008, 100, 898-905.	6.3	94
25	YAP and TAZ in Lung Cancer: Oncogenic Role and Clinical Targeting. Cancers, 2018, 10, 137.	3.7	89
26	Mammosphere-forming cells from breast cancer cell lines as a tool for the identification of CSC-like- and early progenitor-targeting drugs. Cell Cycle, 2010, 9, 2950-2959.	2.6	86
27	miRâ€10b*, a master inhibitor of the cell cycle, is downâ€regulated in human breast tumours. EMBO Molecular Medicine, 2012, 4, 1214-1229.	6.9	85
28	The disruption of the protein complex mutantp53/p73 increases selectively the response of tumor cells to anticancer drugs. Cell Cycle, 2008, 7, 3440-3447.	2.6	83
29	MYC Is Activated by USP2a-Mediated Modulation of MicroRNAs in Prostate Cancer. Cancer Discovery, 2012, 2, 236-247.	9.4	82
30	Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy. Cell Cycle, 2008, 7, 1870-1879.	2.6	81
31	From p63 to p53 across p73. FEBS Letters, 2001, 490, 163-170.	2.8	79
32	Melatonin triggers p53Ser phosphorylation and prevents DNA damage accumulation. Oncogene, 2012, 31, 2931-2942.	5.9	75
33	Epigenetic silencing of miR-145-5p contributes to brain metastasis. Oncotarget, 2015, 6, 35183-35201.	1.8	75
34	Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop. Cell Cycle, 2011, 10, 4330-4340.	2.6	74
35	Long Non-coding MIR205HG Depletes Hsa-miR-590-3p Leading to Unrestrained Proliferation in Head and Neck Squamous Cell Carcinoma. Theranostics, 2018, 8, 1850-1868.	10.0	65
36	Urinary 6-Sulphatoxymelatonin Levels and Risk of Breast Cancer in Premenopausal Women: The ORDET Cohort. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 729-737.	2.5	60

#	Article	IF	Citations
37	Oncogenic Intra-p53 Family Member Interactions in Human Cancers. Frontiers in Oncology, 2016, 6, 77.	2.8	59
38	Metformin-induced ablation of microRNA 21-5p releases Sestrin-1 and CAB39L antitumoral activities. Cell Discovery, 2017, 3, 17022.	6.7	59
39	Tumor suppressor microRNAs: A novel nonâ€coding alliance against cancer. FEBS Letters, 2014, 588, 2639-2652.	2.8	58
40	miR-96-5p targets PTEN expression affecting radio-chemosensitivity of HNSCC cells. Journal of Experimental and Clinical Cancer Research, 2019, 38, 141.	8.6	55
41	YAP/TAZ and EZH2 synergize to impair tumor suppressor activity of TGFBR2 in non-small cell lung cancer. Cancer Letters, 2021, 500, 51-63.	7.2	54
42	Blockage of melatonin receptors impairs p53-mediated prevention of DNA damage accumulation. Carcinogenesis, 2013, 34, 1051-1061.	2.8	52
43	MCM7and its hosted miR-25, 93 and 106b cluster elicit YAP/TAZ oncogenic activity in lung cancer. Carcinogenesis, 2017, 38, 64-75.	2.8	52
44	Mammosphere-forming cells from breast cancer cell lines as a tool for the identification of CSC-like- and early progenitor-targeting drugs. Cell Cycle, 2010, 9, 2878-87.	2.6	51
45	Multitargeting activity of miR-24 inhibits long-term melatonin anticancer effects. Oncotarget, 2016, 7, 20532-20548.	1.8	49
46	Mutant p53 proteins: Between loss and gain of function. Head and Neck, 2007, 29, 488-496.	2.0	45
47	MicroRNA expression as predictor of local recurrence risk in oral squamous cell carcinoma. Head and Neck, 2016, 38, E189-97.	2.0	45
48	Altered peritumoral microRNA expression predicts head and neck cancer patients with a high risk of recurrence. Modern Pathology, 2017, 30, 1387-1401.	5.5	44
49	ÎEF1 repressor controls selectively p53 family members during differentiation. Oncogene, 2005, 24, 7273-7280.	5.9	42
50	Mutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers. International Journal of Molecular Sciences, 2017, 18, 961.	4.1	41
51	Gain of function mutant p53 proteins cooperate with E2F4 to transcriptionally downregulate RAD17 and BRCA1 gene expression. Oncotarget, 2015, 6, 5547-5566.	1.8	41
52	Metformin-induced metabolic reprogramming of chemoresistant ALDHbright breast cancer cells. Oncotarget, 2014, 5, 4129-4143.	1.8	40
53	p73 Is Regulated by Phosphorylation at the G2/M Transition. Journal of Biological Chemistry, 2003, 278, 49196-49202.	3.4	37
54	p73-induced apoptosis: A question of compartments and cooperation. Biochemical and Biophysical Research Communications, 2005, 331, 688-693.	2.1	37

#	Article	IF	Citations
55	Change of Conformation of the DNA-binding Domain of p53 Is the Only Key Element for Binding of and Interference with p73. Journal of Biological Chemistry, 2003, 278, 10546-10555.	3.4	36
56	ChIP-on-Chip Analysis of In Vivo Mutant p53 Binding To Selected Gene Promoters. OMICS A Journal of Integrative Biology, 2011, 15, 305-312.	2.0	36
57	VDR primary targets by genome-wide transcriptional profiling. Journal of Steroid Biochemistry and Molecular Biology, 2014, 143, 348-356.	2.5	36
58	ID4: a new player in the cancer arena. Oncotarget, 2010, 1, 48-58.	1.8	36
59	Cynara scolymus affects malignant pleural mesothelioma by promoting apoptosis and restraining invasion. Oncotarget, 2015, 6, 18134-18150.	1.8	36
60	A Role of p73 in Mitotic Exit. Journal of Biological Chemistry, 2005, 280, 30354-30360.	3.4	35
61	p73-Mediated Chemosensitivity: A Preferential Target of Oncogenic Mutant p53. Cell Cycle, 2003, 2, 345-346.	2.6	34
62	MicroRNAs as Key Effectors in the p53 Network. International Review of Cell and Molecular Biology, 2017, 333, 51-90.	3.2	34
63	Melatonin and Hippo Pathway: Is There Existing Cross-Talk?. International Journal of Molecular Sciences, 2017, 18, 1913.	4.1	34
64	Metformin, diet and breast cancer: An avenue for chemoprevention. Cell Cycle, 2009, 8, 2661-2661.	2.6	33
65	PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2020, 26, 2956-2971.	7.0	33
66	MicroRNA-128-3p-mediated depletion of Drosha promotes lung cancer cell migration. Carcinogenesis, 2018, 39, 293-304.	2.8	32
67	MicroRNAs: short non-coding players in cancer chemoresistance. Molecular and Cellular Therapies, 2014, 2, 16.	0.2	31
68	The miR-205-5p/BRCA1/RAD17 Axis Promotes Genomic Instability in Head and Neck Squamous Cell Carcinomas. Cancers, 2019, 11, 1347.	3.7	31
69	MiRNA-513a-5p inhibits progesterone receptor expression and constitutes a risk factor for breast cancer: the hOrmone and Diet in the ETiology of breast cancer prospective study. Carcinogenesis, 2018, 39, 98-108.	2.8	29
70	microRNAs and cancer metabolism reprogramming: the paradigm of metformin. Annals of Translational Medicine, 2014, 2, 58.	1.7	28
71	Butein impairs the protumorigenic activity of malignant pleural mesothelioma cells. Cell Cycle, 2012, 11, 132-140.	2.6	27
72	MicroRNAs: Non-coding fine tuners of receptor tyrosine kinase signalling in cancer. Seminars in Cell and Developmental Biology, 2016, 50, 133-142.	5.0	27

#	Article	IF	Citations
73	Hippo andrassf1aPathways: A Growing Affair. Molecular Biology International, 2012, 2012, 1-12.	1.7	26
74	Metformin: On Ongoing Journey across Diabetes, Cancer Therapy and Prevention. Metabolites, 2013, 3, 1051-1075.	2.9	26
75	MiR-204 down-regulation elicited perturbation of a gene target signature common to human cholangiocarcinoma and gastric cancer. Oncotarget, 2017, 8, 29540-29557.	1.8	26
76	TMPRSS2, a SARS-CoV-2 internalization protease is downregulated in head and neck cancer patients. Journal of Experimental and Clinical Cancer Research, 2020, 39, 200.	8.6	25
77	ID4: a new player in the cancer arena. Oncotarget, 2010, 1, 48-58.	1.8	25
78	Transcriptional Regulation by Mutant p53 and Oncogenesis. Sub-Cellular Biochemistry, 2014, 85, 91-103.	2.4	24
79	Downregulation of microRNAs 145-3p and 145-5p Is a Long-term Predictor of Postmenopausal Breast Cancer Risk: The ORDET Prospective Study. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2471-2481.	2.5	24
80	Transcriptional activation of the miR-17-92 cluster is involved in the growth-promoting effects of MYB in human Ph-positive leukemia cells. Haematologica, 2019, 104, 82-92.	3.5	24
81	CircPVT1: a pivotal circular node intersecting Long Non-Coding-PVT1 and c-MYC oncogenic signals. Molecular Cancer, 2022, 21, 33.	19.2	23
82	Metformin: Metabolic Rewiring Faces Tumor Heterogeneity. Cells, 2020, 9, 2439.	4.1	22
83	Cdx2 Polymorphism Affects the Activities of Vitamin D Receptor in Human Breast Cancer Cell Lines and Human Breast Carcinomas. PLoS ONE, 2015, 10, e0124894.	2.5	21
84	Oncogenomic Approaches in Exploring Gain of Function of Mutant p53. Current Genomics, 2008, 9, 200-207.	1.6	20
85	Agave negatively regulates YAP and TAZ transcriptionally and post-translationally in osteosarcoma cell lines. Cancer Letters, 2018, 433, 18-32.	7.2	20
86	miR-181c associates with tumor relapse of high grade osteosarcoma. Oncotarget, 2015, 6, 13946-13961.	1.8	20
87	p73-mediated chemosensitivity: a preferential target of oncogenic mutant p53. Cell Cycle, 2003, 2, 348-9.	2.6	20
88	HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome. Oncogene, 2018, 37, 1369-1385.	5.9	19
89	Aberrant transcriptional and post-transcriptional regulation of SPAG5, a YAP-TAZ-TEAD downstream effector, fuels breast cancer cell proliferation. Cell Death and Differentiation, 2021, 28, 1493-1511.	11.2	19
90	microRNAs: short non-coding bullets of gain of function mutant p53 proteins. Oncoscience, 2014, 1, 427-433.	2.2	17

#	Article	IF	Citations
91	Targeting mutant p53 in cancer: the latest insights. Journal of Experimental and Clinical Cancer Research, 2019, 38, 290.	8.6	16
92	Non-coding RNAs as Putative Biomarkers of Cancer-Associated Cachexia. Frontiers in Cell and Developmental Biology, 2020, 8, 257.	3.7	15
93	YAP1 Meets Tumor Suppression. Molecular Cell, 2007, 27, 863-864.	9.7	14
94	PML Surfs into HIPPO Tumor Suppressor Pathway. Frontiers in Oncology, 2013, 3, 36.	2.8	14
95	Targeting a phospho-STAT3-miRNAs pathway improves vesicular hepatic steatosis in an in vitro and in vivo model. Scientific Reports, 2018, 8, 13638.	3.3	14
96	v-Src inhibits myogenic differentiation by interfering with the regulatory network of muscle-specific transcriptional activators at multiple levels. Oncogene, 2003, 22, 8302-8315.	5.9	13
97	The Hippo Tumor Suppressor Pathway: A Brainstorming WorkshopA report on the research meeting â€œThe Hippo Tumor Suppressor Pathway: A Brainstorming Workshopâ€•sponsored mainly by the Regina Elena Cancer Center and the Nicola Foundation and held in Rome, Italy, on 22 and 23 April 2009.. Science Signaling, 2009, 2, mr6.	3.6	13
98	Dropwort-induced metabolic reprogramming restrains YAP/TAZ/TEAD oncogenic axis in mesothelioma. Journal of Experimental and Clinical Cancer Research, 2019, 38, 349.	8.6	13
99	Id2gene is a transcriptional target of the protein complex mutant p53/E2F1. Cell Cycle, 2010, 9, 2464-2466.	2.6	12
100	Allelic Expression Imbalance ofTP53Mutated and Polymorphic Alleles in Head and Neck Tumors. OMICS A Journal of Integrative Biology, 2011, 15, 375-381.	2.0	10
101	Mir 145/143: tumor suppressor, oncogenic microenvironmental factor or ...both?. Aging, 2016, 8, 1153-1155.	3.1	10
102	Arachidonic acid drives adaptive responses to chemotherapy-induced stress in malignant mesothelioma. Journal of Experimental and Clinical Cancer Research, 2021, 40, 344.	8.6	9
103	YAP and TAZ: Monocorial and bicorial transcriptional co-activators in human cancers. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188756.	7.4	9
104	MALAT1-dependent hsa_circ_0076611 regulates translation rate in triple-negative breast cancer. Communications Biology, 2022, 5, .	4.4	8
105	Gender, mutant p53 and PML: A growing â€œaffaireâ€•in tumor suppression and oncogenesis. Cell Cycle, 2013, 12, 1824-1825.	2.6	7
106	Insights into Intra-Tumoral Heterogeneity: Transcriptional Profiling of Chemoresistant MPM Cell Subpopulations Reveals Involvement of NFkB and DNA Repair Pathways and Contributes a Prognostic Signature. International Journal of Molecular Sciences, 2021, 22, 12071.	4.1	7
107	Omics Underpins Novel Clues on VDR Chemoprevention Target in Breast Cancer. OMICS A Journal of Integrative Biology, 2011, 15, 337-346.	2.0	6
108	Comet Assay in Cancer Chemoprevention. Methods in Molecular Biology, 2016, 1379, 99-105.	0.9	6

#	Article	IF	Citations
109	MicroRNA-181a/b: Novel biomarkers to stratify breast cancer patients for PARPi treatment. Cell Cycle, 2013, 12, 1823-1823.	2.6	5
110	What biomarkers (if any) for precise medicine?. Aging, 2015, 7, 533-534.	3.1	4
111	The Transcriptional Coactivator Yes-Associated Protein Drives p73 Gene-Target Specificity in Response to DNA Damage. Molecular Cell, 2005, 19, 429.	9.7	3
112	P73, P63 and Mutant P53: Members of Protein Complexs Floating in Cancer Cells. , 2007, , 223-232.		3
113	YAP and p73: A Matter of Mutual Specificity in Tumor Suppression. , 2013, , 147-172.		3
114	Dihydroartemisinin: from malaria to the treatment of relapsing head and neck cancers. Annals of Translational Medicine, 2020, 8, 612-612.	1.7	3
115	The Hippo tumor suppressor pathway: a report on â€˜the second workshop on the Hippo tumor suppressor pathwayâ€™. Cell Death and Differentiation, 2011, 18, 1388-1390.	11.2	2
116	Cancer Gastric Chemoprevention: Isolation of Gastric Tumor-Initiating Cells. Methods in Molecular Biology, 2016, 1379, 129-137.	0.9	2
117	Antibody Array as a Tool for Screening of Natural Agents in Cancer Chemoprevention. Methods in Molecular Biology, 2016, 1379, 189-199.	0.9	2
118	Lifestyle Factors and MicroRNAs: A New Paradigm in Cancer Chemoprevention. MicroRNA (Shariqah,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.2	2
119	The Conundrum of Giglio Island: Unraveling the dynamics of an apparent resistance to COVID-19 â€“ A descriptive study. Computational and Structural Biotechnology Journal, 2021, 19, 1467-1471.	4.1	1
120	Tetraploidy triggers mithocondria. Cell Cycle, 2009, 8, 1305-1307.	2.6	0
121	Stability strengths oncogenic activity. Cell Cycle, 2010, 9, 1456-1465.	2.6	0
122	Cancer Chemoprevention. Methods in Molecular Biology, 2016, 1379, v.	0.9	0
123	<scp>cTAZ</scp> : a safeguard factor of antiviral response. EMBO Reports, 2019, 20, .	4.5	0
124	Long non-coding RNA MALAT1 as metastasis suppressor. Precision Cancer Medicine, 0, 2, 4-4.	1.8	0
125	p73, p63 and Mutant p53: Members of Protein Complexes Floating in Cancer Cells. , 2007, , 223-232.		0